NEIL STAHL - 02 Feb 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Research and Development
Signature
/s/**Neil Stahl
Issuer symbol
REGN
Transactions as of
02 Feb 2024
Net transactions value
-$9,438,846
Form type
4
Filing time
06 Feb 2024, 16:08:32 UTC
Previous filing
12 Dec 2023
Next filing
08 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $12,289,545 +30,750 +59% $399.66 82,769 02 Feb 2024 Direct
transaction REGN Common Stock Tax liability $21,728,391 -22,713 -27% $956.65 60,056 02 Feb 2024 Direct
holding REGN Common Stock 5,834 02 Feb 2024 By 401(k) Plan
holding REGN Common Stock 4,605 02 Feb 2024 by Spouse as Trustee

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -30,750 -100% $0.000000* 0 02 Feb 2024 Common Stock 30,750 $399.66 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option award vests in four equal annual installments, commencing one year after the date of grant.